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Tight junctions contribute to the paracellular barrier, the fence dividing plasma membranes, and signal transduction, acting as a multifunctional
complex in vertebrate epithelial and endothelial cells. The identification and characterization of the transmembrane proteins of tight junctions,
claudins, junctional adhesion molecules (JAMs), occludin and tricellulin, have led to insights into the molecular nature of tight junctions. We
provide an overview of recent progress in studies on these proteins and highlight their roles and regulation, as well as their functional significance
in human diseases.
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junctional complex in vertebrate epithelial cell sheets (Fig. 1A).
They are also observed in vascular endothelial cells and meso-
thelial cells, as well as several other types of cells (i.e., Schwann
cells, oligodendrocytes and Sertoli cells). By transmission
electron microscopy, tight junctions appear as a series of very⁎ Corresponding author. Tel.: +81 11 611 2111; fax: +81 11 613 5665.
E-mail address: hidchiba@sapmed.ac.jp (H. Chiba).
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doi:10.1016/j.bbamem.2007.08.017close membrane appositions (so-called ‘kissing points’) of
adjacent cells [1]. On freeze–fracture electron microscopy,
these contact sites principally correspond to continuous net-
works of intramembranous particle fibrils (tight junction
strands) (Fig. 1B) and complementary grooves in the proto-
plasmic and extracellular faces, respectively [2].
Tight junctions act as a semipermeable barrier (or gate) to the
paracellular transport of ions, solutes and water, as well as cells,
and are considered to function as a fence that divides apical and
Fig. 1. Apical junctional complex and tight junctions. (A) Schematic drawing of
the junctional complex. (B) Schematic structure of tight junction strands. (C)
Functions of tight junctions. (D) Molecular components of tight junctions. Three
families of tight junction transmembrane proteins, occludin, claudins and JAMs,
as well as some scaffold proteins and polarity proteins are presented.
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see [3–5]). In addition, like other cell–cell and cell–extracellular
matrix junctions (for review, see [6]), tight junctions coordinate a
variety of signaling and trafficking molecules regulating cell
differentiation, proliferation and polarity, thereby serving as
multifunctional complex (for reviews, see [4,7–11]). These
functions of tight junctions are critical for epithelial and endo-
thelial cell sheets to establish distinct tissue compartments within
the body and maintain homeostasis.
Moreover, disturbance of the functions of tight junctions is
considered to cause or contribute to a variety of pathological
conditions, such as inflammatory bowel disease (IBD), infec-
tions and cancers, as well as vasogenic edema and blood-borne
metastasis (for reviews, see [12–18]). In turn, the barrier func-
tion of tight junctions also restricts drug delivery to underlying
tissues and therefore how to overcome the paracellular barrier
(i.e., blood–brain barrier [BBB]) is critical for treatment of
human diseases.
Numerous studies have disclosed various molecular compo-
nents of tight junctions, including the integral membrane pro-teins, occludin [19], claudins [20], junctional adhesion
molecules (JAMs) [21] and tricellulin [22], as well as increasing
numbers of their scaffold proteins (Fig. 1D) (for reviews, see
[4,5,11,12,23–25]). In this section, we will provide overview of
relatively new findings on transmembrane proteins of tight
junctions with focus on their physiological roles and regulation,
as well as on their contributions to human diseases. We will
primarily review mammalian tight junctions.
1. Occludin
Occludin, the first identified component of tight junction
strands, is an approximately 60-kDa tetraspan membrane protein
with two extracellular loops, a short intracellular turn, and N- and
C-terminal cytoplasmic domains [19]. Among these domains, the
first extracellular loop is exceptionally rich in tyrosine and glycine
residues (about 60%) and contains very few charged amino acids.
On the other hand, the long C-terminal domain is rich in serine,
threonine and tyrosine residues, which are frequently phosphor-
ylated by various protein kinases (for reviews, see [7,26]). In
addition, the C-terminal region directly binds to ZO-1 [27], which
in turn associates with the actin cytoskeleton. Although two
isoforms of occludin are produced by alternative splicing [28], no
clear difference in their tissue distribution and functions has been
reported.
Overexpression experiments using full-length and mutated
occludin in Madin–Darby canine kidney (MDCK) cells or Xe-
nopus cells [29,30], as well as a study using a synthetic peptide
corresponding to the second extracellular loop of occludin [31],
initially suggested a role of occludin in the barrier and fence
functions of tight junctions. Surprisingly, by contrast, occludin-
deficient embryonic stem cells differentiated into polarized epi-
thelial cells bearingwell-developed tight junctions that exhibited
no barrier dysfunction [32]. Furthermore, occludin-null mice
were born with no apparent abnormalities in the structure or
barrier function of tight junctions in intestinal epithelia [33].
However, occludin−/−mice showed postnatal growth retardation
and complex phenotypes in various organs, including inflam-
mation and hyperplasia of the gastric mucosa, absence of cyto-
plasmic granules in striated duct cells of the salivary gland, and
thinning of the compact bone, as well as brain calcification and
testicular atrophy, suggesting an unexpected role of occludin.
Several studies have indicated that occludin may be involved
in the transduction of signals. First, forced expression of
occludin suppresses the v-Raf-induced transformation and
tumorigenesis of the salivary gland epithelial cell line Pa4
[34,35]. Second, it has been reported that occludin interacts with
transforming growth factor (TGF)-β type I receptor and
regulates its localization for TGF-β-dependent dissolution of
tight junctions during epithelial-to-mesenchymal transition
(EMT) [36] Third, by using an RNAi approach to knockdown
the expression of occludin in MDCK cells, it has been dem-
onstrated that occludin controls the actin cytoskeleton via
activation of the small GTPase RhoA to extrude apoptotic cells
without altering the degree of apoptosis [37]. Fourth, experi-
ments using hepatocytes from occludin−/− mice have revealed
that occludin inhibits apoptosis through activation of mitogen-
Fig. 2. A model of claudin structure.
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[38]. Fifth, overexpression of occludin in several cancer cells
results in enhanced sensitivity to apoptotic factors via modula-
tion of the expression of apoptosis-related genes, leading to
inhibition of their tumorigenicity [39]. Thus, occludin seems to
function as a signal transmitter from and to tight junctions,
though there are discrepancies concerning the role of occludin in
apoptosis among the latter three studies. In this sense, it is note-
worthy that occludin can also associate with a variety of sig-
naling molecules such as the nonreceptor tyrosine kinase c-Yes,
atypical protein kinase C (aPKC) and PI3-kinase, as well as
protein phosphatases 2A and 1 [40,41] (for review, see [10]).
2. Claudins
2.1. Structure and distribution of claudins
Claudins are 18- to 27-kDa tetraspan proteins with a
short cytoplasmic N-terminus, two extracellular loops and a
C-terminal cytoplasmic domain, and do not show any sequence
similarity to occludin (Fig. 2) [4,20]. Claudins are capable of
forming tight junction strands [42] and thus the backbone of the
tight junction. The claudin family consists of 24 members in
mice and humans and exhibits distinct expression patterns in
tissue- and cell-type-specific manners (for reviews, see [4,43–
45]). The C-terminal cytoplasmic tail of claudins is required for
their stability and targeting [46–48]. In addition, through a
PDZ-binding motif at their C-terminus, claudins directly bind
to PDZ (PSD-95/Dlg/ZO-1) domain-containing peripheral
membrane proteins such as ZO-1, ZO-2, ZO-3, PATJ and
MUPP1 (Fig. 2) [49–51].
More than two claudin species are generally expressed in
most types of epithelial cells (for reviews, see [43–45]). Because
claudins comprise a large gene family as described above, and
some anti-claudin antibodies react not only with the corre-
sponding claudin but also with other claudin species [52], it is of
particular importance to verify the specificity of the antibodies
used. Along this line, we and others have demonstrated, byimmunoblot and immunohistochemical analyses using antibo-
dies that selectively recognize the corresponding claudins
(Fig. 3) [53–55], as well as by gene expression analysis, that
claudin-2 (Cldn2), Cldn3, Cldn4, Cldn7, Cldn8, Cldn12 and
Cldn15 are abundantly expressed in the duodenum, jejunum,
ileum and/or colon with remarkable variations in the expression
levels throughout the segments of the intestinal tract (Fig. 4A)
[55–57]. In addition, these claudin species show distinct
subcellular localization in the intestinal epithelium (Fig. 4B)
[55–57]. Moreover, Cldn2, Cldn4 and Cldn15 are expressed in
gradients along the crypt-to-villous axis of the intestine
(Fig. 4B). Cldn2 is only detected in the deep crypt of the entire
intestine [56–58], and Cldn15 is restricted to the crypt of the
colon with no gradients along the crypt-to-villous axis of the
duodenum, jejunum or ileum [55,57,59]. By contrast, Cldn4 is
predominantly expressed in the upper villi/surface of the whole
intestine [57]. Concerning gradients within tissues, we also have
found that Cldn7 is expressed on cell membranes in Brunner's
glands of the duodenum much less than in the crypt epithelium
[55]. The segment- and/or axis-specific expression of different
claudins has also been reported in several other epithelial tissues,
including the liver lobule [56], nephron [60] and inner ear [61].
Another issue that should be mentioned is basolateral local-
ization of claudins (Fig. 4B). For example, Cldn7 is expressed
more strongly on basolateral surfaces of the intestinal epithe-
lium than on the apical tips [55,57,62]. Similar or identical
patterns of expression are observed for Cldn7 in simple epithe-
lial cells of the lung and kidney [63,64], as well as for Cldn1,
Cldn3 and Cldn4 in the intestinal epithelium [56–58]. Although
the significance of basolateral claudins remains obscure, extra-
junctional claudins may serve as pools for junctional claudins
and alternatively play a role in cell–cell and cell–matrix ad-
hesion and/or signaling [64,65]. In fact, the cell–cell adhesion
molecule EpCAM directly associates with Cldn7 on basolateral
membranes [62], implying a novel role of basolateral claudins.
2.2. Physiological functions of claudins
Claudins, which also show Ca2+-independent cell adhesion
activity [66], are the major determinant of the barrier function of
tight junctions, including the paracellular charge and size
selectivity. This concept has been drawn from studies of claudin
genes using knockout mice (for reviews, see [44]), transgenic
mice [67,68] and in inherited human diseases [69–72], as well
as overexpression experiments using wild-type and mutated
claudins in cultured cell lines as described below.
Importantly, the first extracellular loop, in which there is a
wide variation in the position and number of charged amino acids
depending on each claudin (Fig. 2, unlike occludin, creates
paracellular pores (channels) for selective ions between neigh-
boring cells (for review, see [44,45]). For example, Cldn15 has
two negatively charged residues (positions 53 and 64) in the latter
half of this loop, and substitution of those by positive ones
converts Cldn15 from cation- to anion-permissive [73,74]. In both
mice and humans, Cldn2 has three negatively charged amino
acids (positions 53, 65 and 75) within the first extracellular loop
[74], and Cldn12 contains four negatively charged residues
Fig. 3. Specificity of anti-Cldn1, anti-Cldn5, anti-Cldn6, anti-Cldn7, anti-Cldn8, anti-Cldn12 and anti-Cldn15 antibodies. COS-7 cells were transfected with either
empty or claudin expression vectors. Five μg of total cell lysate was separated by SDS-PAGE and immunoblotted (IB) with the indicated antibodies, followed by
chemiluminescence detection. The transfected mouse claudin cDNAs are indicated at the top of each lane. The mobility of molecular mass markers (kDa) is indicated
on the left. Arrowheads and asterisks indicate specific signals. NS, nonspecific signal.
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that these claudins may also form paracellular pores for cations.
Similarly, Cldn7 likely acts as a paracellular pore to cations [75],
and it contains three negatively charged amino acids within the
first extracellular loop. By contrast, Cldn4, Cldn8 and Cldn14
function primarily in cation barriers [73,76–78], and Cldn13
might create an anion-selective pore as it contains four positively
charged amino acids in the second half of the first extracellular
loop [55]. It is assumed that the combination and proportion of
different claudin species contribute to the barrier properties of
tight junctions in a given cell (tissue) type.
Several lines of evidence have suggested that Cldn16/
paracellin-1 (PCLN-1) plays a key role in the reabsorption of
Mg2+ and Ca2+. First, positional cloning has identified that
familial hypomagnesemia with hypercalciuria and nephrocalci-
nosis (FHHNC), an autosomal recessive disease showing severe
Mg2+ and Ca2+ wasting, is caused by mutations in the Cldn16/
PCLN-1 gene [69]. It is also known that Cldn16 is highly
expressed at tight junctions of epithelial cells in the thickascending loop of Henle, where the reabsorption of divalent
cations occurs [69]. Second, disease-associated mutations in
patients with FHHNC indeed affect the intracellular traffic and
paracellular Mg2+ transport functions of Cldn16 [79]. Third,
forced expression of Cldn16 enhances Mg2+ and Ca2+ transport
inMDCK cells [80,81]. Fourth, using the pig renal epithelial cell
line LLC-PK1 and transgenic mice, Cldn16, which also seems to
cause profound effects on permeability of monovalent cations, is
shown to drive the reabsorption of Mg2+ and Ca2+ [82,83].
On the other hand, Cldn2 is known to act as paracellular
channel to Na+ in renal epithelial cells without altering Cl−
conductance. For instance, overexpression of Cldn2 in MDCK
strain I cells lacking endogenous Cldn2 increases paracellular
Na+ permeability and decreases transendothelial electrical
resistance (TER) [84,85]. Similar effects are observed when
Cldn2 is overexpressed in LLC-PK1 cells expressing little
endogenous Cldn2 [74]. Conversely, knockdown of endogenous
Cldn2 expression in MDCK strain II cells reduces paracellular
Na+ permeation and elevates TER [82].
Fig. 5. Models depicting the enhancement of vascular endothelial barrier by
cAMP and PKA. cAMP induces phosphorylation of Cldn5 protein at Thr207 via
a PKA-dependent pathway and activates expression of the Cldn5 gene in a
PKA-independent manner.
Fig. 4. Differential expression and subcellular localization of claudins along the
mouse intestine. Relative expression levels (A) and schematic distribution (B) of
Cldn2, Cldn3, Cldn4, Cldn7, Cldn8, Cldn12 and Cldn15 in the duodenum,
jejunum, ileum and colon are summarized [47,49]. (A) Bar height represents the
expression level. (B) The colors represent the same claudins as in panel A.
Colored dots and lines correspond to localization at tight junctions and
basolateral membranes, respectively.
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overexpression strategies, that Cldn2 and Cldn12 facilitate
paracellular Ca2+ absorption in intestinal epithelial cells (our
unpublished results).We have also reported that forced expression
ofCldn2, but not Cldn12, in the intestinal epithelial cell lineCaco-
2 results in enhancement of Na+ permeability. Furthermore, we
have demonstrated that expression of Cldn2 and Cldn12 is
upregulated in enterocytes in vitro and in vivo by an active formof
vitamin D3, 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3]. These
findings strongly suggest that Cldn2- and/or Cldn12-based tight
junctions form paracellular Ca2+ channels in intestinal epithelia,
and highlight a novel mechanism behind vitamin D-dependent
calcium homeostasis.Compared with the significance of claudins in charge selec-
tivity, our knowledge on the contribution of claudins to size
selectivity is still fragmentary. In Cldn5-deficient mice, the
BBB is severely affected with regard to small molecules (less
than about 800 Da), but not larger molecules [86]. In contrast,
induced expression of Cldn5 reconstitutes the paracellular
barrier against inulin (5 kDa), but not mannitol (182 Da), in the
leaky rat lung endothelial (RLE) cell line [87]. The discrepancy
concerning the role of Cldn5 in paracellular size selectivity
might be explained by a difference in expression of endogenous
claudins between these endothelial cell types. In other words, at
least Cldn5 and Cldn12 are expressed in BBB endothelial cells
[86], whereas no endogenous claudins are detected in RLE cells
as far as we could determine [87–89].
We should reconsider the role of claudin-based tight junctions
in the fence function. Umeda et al. [90] have recently dem-
onstrated that loss of ZO-1 and ZO-2 in the mouse mammary
epithelial cell line Eph4 lacking endogenous ZO-3 completely
disrupts the polymerization of claudins and formation of tight
junctions, but surprisingly does not perturb overall apicobasal
cell polarity (i.e., formation of microvilli and cell junctions, as
well as the asymmetrical distribution of membrane proteins)
even if polarity proteins PAR-3, aPKC and Pals1 are localized in
lateral membranes. These findings strongly suggest that claudin-
based tight junctions are dispensable for the fence function, at
least in monolayer culture of mature epithelial cells [91].
2.3. Physiological regulation of claudins
Concerning posttranslational modification of claudins, we
have reported that cyclic AMP (cAMP)-dependent protein kinase
(PKA) phosphorylates Cldn5 at Thr207, which is accompanied by
enhanced detergent insolubility and junctional immunoreactivity
of Cldn5, as well as a change in the barrier function of tight
junctions (Fig. 5) [53,87]. Since detergent insolubility of proteins
is considered to indicate their integration into macromolecular
complexes such as intercellular junctions, phosphorylation of
claudins might be involved in its incorporation into tight
junctions, leading to promotion of tight junction functions. Note
that gene expression of Cldn5 in brain microvascular endothelial
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indicating that cAMP regulates Cldn5 and elevates the barrier
function via PKA-dependent and -independent pathways [53]. It
is also reported that PKA phosphorylates Cldn16, resulting in
enhancement of its detergent insolubility and junctional localiza-
tion [81]. By contrast, PKA-dependent phosphorylation of Cldn3
leads to its cytoplasmic localization and barrier dysfunction in
ovarian cancer cells [92].
Several other protein kinases also phosphorylate claudins at
their C-terminal tail and influence the barrier function of tight
junctions. For example, we demonstrated that MAPK promoted
phosphorylation of Cldn1 at Thr203 and increased its insolubility
to detergent and the barrier function [88]. PKC is also known to
phosphorylate Cldn1 [93,94] and Cldn4 [92]. In addition, it has
been shown that WNK4 phosphorylates Cldn1, Cldn2, Cldn3
and Cldn4, and that the disease (pseudohypoaldosteronism type
II)-causing mutant increases their phosphorylation levels [95].
Moreover, the receptor tyrosine kinase EphA2 associates with
Cldn4 via their extracellular domains and phosphorylates Cldn4
in the C-terminal tail at Tyr208, resulting in inhibition of its
interaction with ZO-1 and reduction of its integration into cell
junctions, as well as barrier dysfunction of tight junctions [96].
As another type of posttranslational modification, it has been
reported that Cldn2, Cldn4 and Cldn14 are palmitoylated [97].
Palmitoylation of Cldn14 at two sets of membrane-proximal
cysteins following the second and forth transmembrane do-
mains, which are well conserved among claudin species, is re-
quired for efficient tight junction localization and function [97].
Among transcription factors, the nuclear receptor superfam-
ily is one of the most important for regulating expression of
claudins. First, we found that two types of nuclear receptors,
retinoid receptors and hepatocyte nuclear receptor 4α (HNF4α),
triggered expression of Cldn6 and Cldn7 in the embryonal
carcinoma cell line F9 [54,98,99]. Subsequently, Cldn1 was
shown to be absent in hepatocytes in mice with conditional
knockout of the HNF4α gene [100]. Note that HNF4α acts as a
morphogen to induce the formation of cell junctions [54,99–
101] and microvilli [102], establishing at least two aspects of
apicobasal cell polarity. It is also reported that retinoid receptors
and the kinase IKK1 cooperatively regulate the expression of
retinoid target genes, including Cldn23, in keratinocytes [103].
In addition, comparison of gene expression profiling between
wild-type and Sertoli cell-specific androgen receptor (AR)-
knockout mice revealed that AR mediated activation of the
Cldn3 expression in Sertoli cells [104]. Furthermore, we have
recently provided evidence showing that expression of Cldn2
and Cldn12 is upregulated in enterocytes in vitro and in vivo by
1α,25(OH)2D3 through its receptor VDR (our unpublished
results). Taken collectively, expression of different claudin
species seems to be upregulated by distinct members of the
nuclear receptor superfamily in a cell-specific manner.
Regarding regulation of Cldn2 expression, the caudal-related
homeobox proteins Cdx1 and Cdx2 activate its gene expression,
and HNF1α augments the Cdx2-induced transcriptional activa-
tion of the human Cldn2 promoter [105]. In addition to Cdx2
and HNF1α, GATA4 cooperatively upregulates expression of
the Cldn2 gene [106]. Cldn2 expression is also upregulatedthrough activation of RhoA and c-Jun N-terminal kinase (JNK)
[107]. On the other hand, activation of MAPK is known to
downregulate Cldn2 expression in several epithelial cell types
[38,108,109], although MAPK activation by the inflammatory
cytokine IL-17 upregulates Cldn1 and Cldn2 expression in the
human intestinal cell line T84 [110].
For other regulators of claudin expression, there is a review
summarizing data on the topics [45]. Among them, we should
mention that the transcriptional repressor SNAI1 (Snail
homologue 1) downregulates the expression of Cldn3, Cldn4
and Cldn7 [111] in Eph4 epithelial cells and Cldn1 in MDCK
cells [112] during EMT. It is of particular interest that SNAI1
binds the promoter of VDR and HNF4α genes and represses
their expression [113,114] (for review, see [115]). Hence, SNAI1
directly and indirectly inhibits the expression of several claudin
species.
2.4. Claudins and human disease
To date, mutations in four claudin genes have been reported
to cause human hereditary diseases. First, various mutations in
the Cldn16 gene were identified in patients with FHHNC as
mentioned above [69,79,116]. Second, mutations in the Cldn14
gene, the expression of which is abundantly observed in outer
hair cells of the cochlea, cause autosomal recessive deafness
[70,117]. Third, mutations in the Cldn1 gene are reported in
neonatal sclerosing cholangitis with ichthyosis [71]. Fourth,
mutations in the Cldn19 gene, whose expression is highly
detected in renal tubules and the retina, have recently been
identified in families affected with severe hypomagnesemia due
to renal wasting, nephrocalcinosis, progressive renal failure and
severe ocular abnormalities [72].
Unlike other junction molecules, expression of claudins is
often increased in various cancers. For example, Cldn3, Cldn4
and Cldn7 are frequently upregulated in a variety of cancers
such as those originating from the ovary, fallopian tubes, breast,
uterus, prostate, thyroid, pancreas, stomach, colon and bladder
[18,118–120]. Since not only Cldn3/RVP1 (rat ventral prostate-
1) [121] and Cldn4/CPE-R (receptor for Clostridium perfrin-
gens enterotoxin [CPE]) [122], but also Cldn7, bind to CPE
with high affinity (Fig. 2) [123,124], these claudins are expected
to be promising targets of CPE-mediated therapy for cancers.
Although the exact roles of overexpressed claudins in cancer are
unclear, expression of some claudins in epithelial cells promotes
cell invasion, motility and/or survival [125,126] (for review, see
[109]), suggesting potential functions of claudins in tumori-
genesis and metastasis. On the other hand, it is noteworthy that
reduced expression of Cldn4 and Cldn7 at the invasive front of
colorectal and esophageal cancer, respectively, significantly
correlates with tumor invasion and metastasis [127,128].
The expression and/or distribution of claudins are also
altered in numerous other pathological conditions, and these
changes are proposed to play important roles in the pathophys-
iology of such diseases. For instance, the interferon-γ-triggered
internalization of claudin-1 and -4, as well as that of occludin
and JAM-A, was suggested to contribute to the pathogenesis
and barrier dysfunction in IBD using the human intestinal
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hypoxia, which disrupts the barrier properties of neural vascular
endothelial cells and accelerates the progression of disorders
such as cerebral ischemic diseases and diabetic retinopathy, is
reported to provoke a reduction in expression levels of Cldn5
protein and its disappearance from the plasma membrane [130].
Interestingly, we have found that retinoids increase and decrease
the expression of glial cell line-derived neurotrophic factor
(GDNF) and vascular endothelial growth factor (VEGF) in glial
cells, respectively, attenuating the barrier dysfunction of
vascular endothelial cells in diabetic retinopathy [131].
Recently, Cldn1 was identified as a coreceptor for hepatitis C
virus (HCV) and shown to be required for HCV entry into host
cells (Fig. 2) [132]. It has also been reported that ectopic
expression of Cldn1 in non-hepatic cells confers susceptibility
to HCV infection. In addition, the C-terminal portion within the
first extracellular loop of Cldn1 is critical for HCV suscepti-
bility (Fig. 2).
3. Tricellulin
Tricellulin has been identified as a four-pass transmembrane
protein that that is concentrated at the vertically oriented tight
junction strands of tricellular contacts of epithelial cell sheets
[133]. Its C-terminal sequence (∼130 amino acids) is 32%
identical to that of occludin, whereas the N-terminal cytoplas-
mic domain is longer than that of occludin. Tricellulin is phos-
phorylated, and its expression is repressed by SNAI1. Using an
RNAi approach, it has been shown that tricellulin participates in
the epithelial barrier and organization of not only tricellular tight
junctions but also bicellular tight junctions. More recently, it has
been found that recessive mutations in the tricellulin gene cause
nonsyndromic deafness (DFNB49), and that tricellulin in fact is
assembled at tricellular tight junctions in cochlear and vestibular
epithelial cells [134]. Interestingly, in spite of its ubiquitous
distribution in epithelial cells, the only phenotype of the tri-
cellulin mutations appears to be deafness. It is also reported that
multiple isoforms of tricellulin are generated by alternative
splicing.
4. Junctional adhesion molecules
JAMs are glycosylated transmembrane proteins that belong
to the immunoglobulin (Ig) superfamily and consist of two
extracellular Ig-like domains, a single transmembrane region
and a C-terminal cytoplasmic domain. The JAM family is di-
vided into two subgroups based on their sequence similarities
(for reviews, see [24,25]). The first subgroup, JAM-A (also
designated JAM/JAM-1/106 antigen/F11R), JAM-B (also
known as VE-JAM/mJAM-3/hJAM-2) and JAM-C (also
named mJAM-2/hJAM-3) has a class II PDZ domain-binding
motif at their C-terminal ends, and directly interacts with ZO-1
and PAR-3 [135–137]. By contrast, members of the second
subgroup, coxsackie and adenovirus receptor (CAR), endothe-
lial cell-selective adhesion molecule (ESAM) and JAM4 contain
a class I PDZ domain-binding motif at their C-terminus. CAR
and JAM4 associate with Ligand-of-Numb protein X1 (LNX1)[138,139], and JAM4 and ESAM bind to the membrane-
associated guanylate kinase protein (MAGI-1) [140,141].
In addition to association with intracellular binding partners,
JAMs show homophilic and heterophilic interactions through
their extracellular domains (for reviews, see [24,25,142]).
Moreover, JAMs exhibit heterophilic interactions via the
extracellular domains with β1 and β2 integrins. So far, it has
been reported that JAM-A, JAM-B and JAM-C interact with
integrins αLβ2 (LFA-1), α4β1 (VLA-4) and αMβ2 (Mac-1),
respectively, which are found on circulating blood cells (for
reviews, see [24,25,142]). Since JAMs are expressed on
endothelial cells, epithelial cells and/or blood cells, they function
as cell–cell adhesion molecules not only between the same types
of cells but also among distinct types of cells (i.e., leukocytes,
platelets and/or endothelial cells) through homophilic and
heterophilic interactions.
4.1. JAM-A, JAM-B and JAM-C
JAM-A is involved in the barrier function of tight junctions
in both endothelial and epithelial cells [21,143,144], and de-
velopment of apicobasal cell polarity in epithelial cells [145]. It
is also reported that JAM-B and JAM-C are found on Sertoli
cells and spermatids, respectively, and that JAM-C is essential
for the polarization of round spermatids [146]. JAM-A
represents not only a component of tight junctions but also a
receptor for reoviruses [147].
JAM-A also participates in monocyte transmigration [21]. In
addition, by analyzing JAM-A−/− mice, endothelial JAM-A−/−
mice and/or those treated with an anti-JAM-A antibody, JAM-A
was revealed to control transmigration of neutrophils, but not
lymphocytes, across endothelial cells [148,149]. In addition to
JAM-A, JAM-C is involved in transmigration of neutrophils
and monocytes across endothelial and epithelial cells [150–153]
(for reviews, see [44,45,142]). On the other hand, JAM-A also
regulates endothelial cell migration [154–156]. Furthermore, it
is demonstrated that dendritic cells (DCs), in which occludin
and Cldn1 are found [157], also express JAM-A, and JAM-A-
deficient mice show enhanced motility of DCs and their
migration to lymph nodes [158].
Another issue that should be mentioned is the role of JAM-C
in the malignant potential and angiogenesis of tumors. First,
homophilic interaction of JAM-C occurs between tumor cells
and endothelial cells [159]. Second, JAM-C is expressed in
most cancer cells showing metastatic properties and promotes
metastasis of the human fibrosarcoma cell line HT1080 by
enhancing its adhesion to extracellular matrices and the sub-
sequent invasion [160]. Third, JAM-C is implicated in
angiogenesis of tumor grafts and hypoxia-induced neovascular-
ization, suggesting that JAM-C may be a putative target for
antitumor therapies [161].
4.2. CAR, ESAM, JAM4
CAR contributes to the barrier function of tight junctions in
epithelial cells [162,163]. It is predominantly expressed in a
variety of epithelial cells lining the body cavities, but not
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interaction with neutrophil JAML (JAM-like molecule, [165]),
thereby modulating neutrophil migration [166]. CAR is also
concentrated in intercalated discs between cardiomyocytes
[164,167] and is essential for early embryonic cardiomyocyte
development [168,169]. In addition, CAR-like membrane
protein (CLMP) has also been identified [170].
Coyne and Bergelson [171] have demonstrated the mecha-
nism by which group B coxsackieviruses (CVBs) approach
from the apical surface of polarized epithelial cells and access
CAR in tight junctions. In brief, the attachment of CVBs to the
GPI-anchored protein decay-accelerating factor (DAF) on the
apical membrane provokes two independent signaling pathways
required for viral entry: activation of tyrosine kinase Abl
initiates Rac-dependent actin rearrangements that permit virus
movement to tight junctions, where association with CAR leads
to conformational changes in the virus capsid that are essential
for viral entry and release of viral RNA; in parallel, activation of
Src tyrosine kinase Fyn phosphorylates and activates caveolin-
1, which in turn promotes virus internalization into vesicles
[171,172].
ESAM is restricted to endothelial cells and platelets, but not
epithelial cells or leukocytes [173,174]. ESAM−/−mice show no
obvious abnormalities in physiological angiogenesis but exhibit
impairment in pathological angiogenesis such as in tumor
growth [175]. Extravasation of neutrophils, but not recruitment
of lymphocytes, is also significantly reduced in ESAM-deficient
mice at an early step of the inflammatory process [176]. In
addition, loss of ESAM enhances VEGF-initiated permeability
[176]. JAM4−/− mice are reported to possess no apparent abnor-
malities as far as examined [177].
5. Conclusions
The discoveries of occludin, claudins, JAMs and tricellulin
were undoubtedly breakthroughs in the field and have greatly
contributed to our understanding of the molecular nature of tight
junctions. Recently, Bves (blood vessel/epicardial substance)/
Pop1a, which belongs to the Popeye family Popdc (Popeye
domain containing), has been suggested to be another trans-
membrane protein of tight junctions [178,179]. Bves is predicted
to be a three-pass integral membrane protein with an extra-
cellular N-terminus and an intracellular C-terminal domain, and
its sequence is well conserved across a variety of vertebrate
species. The majority of Bves is ultrastructurally found at tight
junctions of polarized epithelial cells, and it is involved in the
epithelial barrier. Thus, our knowledge on integral membrane
proteins of tight junctions has been accumulated, several
unanswered questions remain.
First, the structural basis for claudin-based paracellular pores
(channels) should be characterized by electron crystallography.
This will help us to understand the mechanisms by which
claudins determine the paracellular charge and size selectivity.
Second, the undefined roles of tight junction transmembrane
proteins must be determined. For instance, overexpression of
Cldn1 on the right side but not on the left side of the chick
embryo results in abnormal heart looping [94]. The exact func-tions of extrajunctional claudins also remain to be elucidated.
Third, the functional relevance of posttranslational modifica-
tions of claudins must be determined. Fourth, the significance of
tight junction membrane proteins in human diseases should be
further clarified. Do several pathogens access their cognate
receptors in tight junctions via mechanisms similar to those by
which CVBs target CAR? How do tight junction proteins con-
tribute to carcinogenesis and metastasis? Finally, are there other
proteins that are concentrated at tricellular tight junctions? In
addition, it should also be examined how cells and substances
pass through tricellular contact sites.
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